CClinicalTrials.gg
Sign In
CompletedNCT03973164PMRILUpdated Jun 4, 2019

The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma

An observational study in Lymphoma, sponsored by Guangxi Medical University. Completed at 1 site in China. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2019-06-04.

Sponsored by Guangxi Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
142
Ages
8 Years and older
Sex
All
01

Study summary

The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.

02

Conditions studied

  • Lymphoma

Browse trials for

03

In context

Lymphoma

5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.

This study's enrollment of 142 is close to the median of 136 across 625 observational studies indexed under Lymphoma.

Browse Lymphoma studies →

Lead sponsor

Guangxi Medical University is the lead sponsor of 68 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population was an Asian race with lymphoma.

Inclusion criteria

  • Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
  • Patients who gave written informed consent were referred for MRI.
  • Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, general contraindications to MRI.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
142 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis

    MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up.

    Time frame: Within 30 days prior to start of chemotherapy

Secondary outcomes

  1. Agreement Between MRI and 18F-FDG PET/CT at Diagnosis

    Region based agreement (%; kappa value) of MRI with 18F-FDG PET/CT at diagnosis.

    Time frame: Within 30 days prior to start of chemotherapy

07

Study locations

1 site
  • Affiliated Tumor Hospital，Guangxi Medical University
    Nanning, China
08

References and documents

Publications

  • Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229. Erratum In: J Clin Oncol. 2016 Jul 20;34(21):2562. doi: 10.1200/JCO.2016.68.9265. PubMed 25113771 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03973164
Lead sponsor
Guangxi Medical University
Responsible party
Chengcheng Liao (Principal Investigator, Guangxi Medical University) — Principal investigator
First posted
Jun 4, 2019
Start date
Feb 2, 2018
Primary completion
May 22, 2019
Completion
May 22, 2019
Last update
Jun 4, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lymphoma→

Other studies from this sponsor

Guangxi Medical University

Start the discussion